Clinical Trial Update: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) [EARLY_Phase 1]

View source ↗

Summary

An early-phase (EARLY_PHASE1) clinical study of B001 Injection in Neuromyelitis optica spectrum disorder is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• B001 Injection

Snippet

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd | Conditions: NMO Spectrum Disorder | EARLY_Phase 1 | Status: RECRUITING